Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the closing of the recent trading day, TransMedics (TMDX) stood at $84.74, denoting a +0.69% change from the preceding trading day.
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
TransMedics (TMDX) reachead $91.82 at the closing of the latest trading day, reflecting no change compared to its last close.
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...
Whether you believe them or not, analyst ratings have long been a strong indicator of the stock price’s direction. There is a direct correlation between how Wall Street analysts rate a stock and how it performs. After all, analysts aren’t just pulling these price targets out of thin air. They use complex formulas that include analyzing the company’s past and present fundamentals to predict its future price multiple. So should we blindly follow analyst ratings or price targets? We shouldn’t ever
Many investors might overlook MedTech healthcare stocks as the next goldmine of the stock market, but these companies often demonstrate unlimited potential. Unlike their pharma counterparts, for example, MedTech healthcare stocks are often nimbler and more innovative. This positions the sector to better adapt to changing market conditions and industry trends. Furthermore, many top MedTech stocks leverage global trends similar to those that propelled stocks like Nvidia (NASDAQ:NVDA) to rapid succ
Organ transplant firm TransMedics has soared past a buy point amid a six-day rally even as the S&P 500 has come off its recent highs.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on April 4, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 9,722 shares of its common stock and an aggregate of 6,322 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The gr